BioCentury
ARTICLE | Company News

Gilead acquires EpiTherapeutics

May 7, 2015 2:30 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) acquired epigenetics company EpiTherapeutics ApS (Copenhagen, Denmark) for $65 million in cash, subject to undisclosed adjustments.

EpiTherapeutics is developing preclinical small molecule inhibitors of histone demethylases to treat cancer. Gilead declined to discuss its plans for EpiTherapeutics' candidates. ...